Major A, Smith DE, Ghosh D, et al. - In view of previous studies demonstrating an increased risk of secondary primary malignancies (SPMs) after diffuse large B-cell lymphoma (DLBCL) treatment, researchers examined if the stage of DLBCL at diagnosis affects the subtypes of SPMs that occur. Investigating the Surveillance, Epidemiology, and End Results database, they identified 26,038 patients with DLBCL, including 14,724 with early stage (ES) (stage I-II) and 11,314 with advanced stage (AS) (stage III-IV) disease. SPM developed in 13.0% of patients; those who had ES disease were identified to be at a higher but nonsignificantly increased risk of SPM development when compared with those who had AS disease (14% vs 11.6%). During the first 5 years after diagnosis, a higher risk of SPM, specifically colorectal, pancreas, breast, and prostate SPMs, was observed among patients who had ES disease relative to those who had AS disease. During the period from 10 to 15 years after diagnosis, a higher risk of SPM, specifically hematologic SPMs, was evident among patients who had AS disease than those who had ES disease. The risk of death significantly increases with the development of SPM; this was observed regardless of stage at diagnosis.